DoW Breast Cancer, Transformative Breast Cancer Consortium Award
Closed Posted
- Opportunity number
- HT942526BCRPTBCCA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Department of the Army Medical Command, through the Congressionally Directed Medical Research Programs, is soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Transformative Breast Cancer Consortium Award on or before September 30, 2026, with a single award of approximately $35 million and a maximum four-year period of performance. Applicants must be extramural or intramural U.S. Department of War organizations, including foreign and domestic entities, for-profit and nonprofit organizations, and public or private entities; no cost share is required. The award ceiling is $35 million combined total costs for the entire consortium, with no stated floor.
The consortium must comprise at least four but no more than five project teams, with no more than two project teams based at a single institution, led by a Consortium Director (one Principal Investigator) and three to four Project Team PIs. Each PI must commit appropriate effort; the Consortium Director must maintain a minimum 25% time and effort commitment to direct and manage the consortium while leading their own project team. At least one breast cancer consumer advocate must be included per project team. Only the Consortium Director submits a pre-application (due June 12, 2026 at 5:00 p.m. ET), but all PIs must submit at the full application stage; failure to submit all associated applications by September 30, 2026 at 11:59 p.m. ET may result in administrative withdrawal.
Applications must address at least one of nine specified FY26 Breast Cancer Research Program overarching challenges or provide adequate justification for exception. Research must demonstrate transformative impact on individuals with or at risk for breast cancer through innovative, paradigm-shifting work that a single investigator or group could not accomplish. Applicants must submit detailed integration, research management, and consortium management plans, and commit to annual in-progress review meetings and biannual consortium workshops. Seed project funding up to 5% of total direct budget costs is permitted. Clinical trials up to Phase 1 are permitted but not required. Funding is provided as a cooperative agreement based on anticipated substantial government involvement. Awards will be made no later than September 30, 2027, using FY26 funds that expire for use on September 30, 2032. The funding opportunity number is HT942526BCRPTBCCA; CFDA 12.420.
Synopsis
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium's collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.
Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.
Files
| File | Type | Posted |
|---|---|---|
| PKG00292642.pdf | ||
| HT942526BCRPTBCCA_GG.pdf | ||
| HT942526BCRPTBCCA_GG.pdf | ||
| HT942526BCRPTBCCA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity